ensovibep

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Molecular Partners AG

Conditions

Ambulatory Symptomatic COVID-19 infected patientsCOVID-19Covid19

Phase 1

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

TerminatedNCT04870164

Molecular Partners AGCOVID-19

Start: 2020-11-18End: 2022-01-06Updated: 2022-03-18

Phase 2

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

TerminatedNCT04828161

Novartis PharmaceuticalsCOVID-19

Start: 2021-05-10End: 2022-01-27Updated: 2026-01-27

Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

CompletedNCT04834856

Molecular Partners AGCovid19

Start: 2021-04-01End: 2021-08-20Updated: 2021-09-08

A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19 – The “EMPATHY” Trial

Active, not recruitingPACTR202107832151388

Molecular Partners AGAmbulatory Symptomatic COVID-19 infected patients

Start: 2021-04-15Target: 2100Updated: 2026-08-03

Related Papers

The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study

Open Forum Infectious Diseases2024-05-033 citations

Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial

10.01 - Respiratory infections and bronchiectasis2022-09-04